期刊文献+

血清纤维化指标对排血分数正常心力衰竭诊断意义 被引量:2

SERUM FIBROSIS INDEX IN THE DIAGNOSIS OF HEART FAILURE WITH NORMAL LEFT VENTRICULAR EJECTION FRACTION
下载PDF
导出
摘要 目的研究血清纤维化指标在排血分数正常的心力衰竭(HFNEF)诊断中的意义。方法选取我院心内科住院病人100例,分为HFNEF组(54例)和无心力衰竭症状的冠心病病人组(对照组,46例)。采用放射免疫分析法,检测两组病人治疗前后血清中Ⅰ型前胶原(PCⅠ)、Ⅲ型前胶原(PCⅢ)、透明质酸(HA)的水平。结果 HFNEF组病人治疗前血清PCⅠ、PCⅢ和HA的水平明显高于对照组,差异有显著性(t=2.56~4.06,P<0.05);HFNEF组病人抗纤维化治疗前后血清PCⅠ、PCⅢ和HA水平比较,差异有显著性(t=5.05~6.15,P<0.05)。结论 PCⅠ、PCⅢ和HA可以作为HFNEF的辅助诊断指标;抗纤维化治疗对HFNEF病人有效。 Objective To assess the diagnostic significance of serum fibrosis indexes (SFI) in heart failure with normal ejection fraction (NEF). Methods One hundred hospitalized patients in department of cardiology were divided into heart failure with NEF (observation group) and coronary heart disease group without heart failure (control group). Using immunoradiometric analysis, the serum levels of type I collagen (PC Ⅰ ), type Ⅲ collagen (PCⅢ), and hyaluronie acid (HA) were detected in both group-before and after treatment. Results Serum PC I , PCⅢ and HA of patients in the observation group before therapy were obviously higher than that in the control group, the differences being significant (t = 2.56-4.06,P〈0.05), and the differences of serum levels of PC Ⅰ , PCⅢ, HA, between before and after antifibrotic therapy, in the observation group were significant (t = 5.05-6.15,P〈0.05). Conclusion PC Ⅰ , PCⅢ , and HA can be used as indexes for auxiliary diagnosis of heart failure with NEF, and antifibrotic therapy is effective for this condition.
出处 《青岛大学医学院学报》 CAS 2013年第5期415-416,共2页 Acta Academiae Medicinae Qingdao Universitatis
关键词 心力衰竭 胶原Ⅰ型 胶原Ⅲ型 诊断 heart failure collagen type Ⅰ collagen type Ⅲ diagnosis
  • 相关文献

参考文献9

二级参考文献54

  • 1冷文修,何昆仑,范利.老年舒张性心力衰竭发病机制研究进展[J].中华老年心脑血管病杂志,2005,7(2):141-142. 被引量:18
  • 2徐倩,商永芳,袁鹰,苗志敏.脑利尿钠肽与早期糖尿病肾病的关系[J].齐鲁医学杂志,2006,21(2):144-145. 被引量:3
  • 3周伟,石学宁,杨立森.血浆脑钠素与老年性左心室舒张功能不全的相关性探讨[J].宁夏医学院学报,2006,28(5):392-393. 被引量:2
  • 4戴敏,杨俊华,徐苏丹,王惠芬,周炳元,赵彩明,宋建平.应用心衰超声指数评价舒张性心力衰竭的临床价值[J].中国实用内科杂志,2006,26(11):1706-1708. 被引量:23
  • 5European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure[J]. Eur Heart, 1998,19(7): 990-1003.
  • 6KATZ A M, ZILE M R. New molecular mechanism in diastolic heart failure[J]. Circulation JT Circulation, 2006,113 (16) :1922-1925.
  • 7PEMBERTON C J, JOHNSON M L, YANDLE T G, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J]. Hypertension, 2000,36 : 36 (3): 355-359.
  • 8MUELLER T, GEGENHUBER A, POELZ W, et al. Head to head comparison of the diagnostic utility of BNP and NT proBNP in symptomatic and asymptomatic structural heart disease[J]. ClinChim Acta, 2004:341(1-2) :41- 48.
  • 9TSCHOPE C, KASNER M, WESTERMANN D, et al. The role of NT proBNP in the diagnostics of isolated diastolic dysfunction:correlation with echocardiographic and invasive measurements[J]. Eur Heart J , 2005:26(21):2277-2284.
  • 10NAKAO S, GODA A, YUBA M, et al. Characterization of left ventricular filling abnormalities and its relation to elevated plasma brain natriuretic peptide level in acute to chronic diastolic heart failure[J]. Circ J JT-Circulation Journal of Ficial Journal of the Japanese Circulation Society, 2007, 71 ( 9 ) : 1412 -1417.

共引文献32

同被引文献23

  • 1李潞,赵红丽,王宇,张慧芳.冠心病充血性心力衰竭患者心肌纤维化水平及缬沙坦对其的影响[J].中国心血管杂志,2006,11(3):185-186. 被引量:5
  • 2Takashio S,Yamamuro M,Uemura T,et al.Correlation be- tween extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in pa- tients with nonischemic heart failure[J].Am J Cardiol,2014, 113(10) : 1697-1704.
  • 3Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail,2013,15:110- 118.
  • 4Little WC, Zile MR. HFpEF:eardiovascular abnormalities not just comorbidities. Circ Heart Fail, 2012,5 : 669-671.
  • 5Lok DJ, Lok SI, Bmggink-Andr6 de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Car- diol, 2013,102 : 103-110.
  • 6Lam CS, Donai E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail,2011,13: 18-28.
  • 7Liu ~, Haddad T, Dwivedi G. Heart failure with preserved ejec- tion fraction: current understanding and emerging concepts. Curt Opin Cardiol, 2013,28 : 187-196.
  • 8Poss J, Ewen S, Link A, et al. Acute and chronic heart failure- innovations of the new ESC guidelines and their underlying clini- cal trims. Dtsch Med Wochenschr,2013,138:1360-1364.
  • 9Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coil Cardiol, 2012,60 : 1249-1256.
  • 10Gruson D, Ko G. Galeetins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem, 2012,45 : 719-726.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部